Last Update 01 Jun 26

SFZN: Steady 2026 Guidance And Refined Views Will Support Future Upside

Analysts have modestly raised their average price target on Siegfried Holding by CHF 4 to reflect updated views on valuation, with one firm lifting its target by CHF 4 while another recently adjusted its target down to CHF 96, keeping expectations broadly in line with prior assumptions.

Analyst Commentary

Bullish Takeaways

Bullish analysts see room for upside in the share price, reflected in the CHF 4 upward adjustment. This signals confidence that the current valuation still leaves some headroom.
The modest lift in targets points to expectations that the company can continue to execute on its plans without major disruption. This supports a steady equity story rather than a binary one.
By keeping targets close to prior levels, bullish analysts indicate that recent information has broadly confirmed their existing view on the business, rather than forcing a sharp rethink of its potential.
The upward revision, even if small in absolute terms, shows that analysts are willing to fine tune their models in a supportive direction rather than trimming forecasts.

Bearish Takeaways

Bearish analysts have set a CHF 96 target, which flags concern that the stock may already discount much of the medium term opportunity and could have limited upside from current levels.
The cut from CHF 108 to CHF 96 suggests increased caution around execution risks or the pace at which growth might translate into earnings, even if the business remains fundamentally intact.
Maintaining a Sector Perform stance alongside a lower target indicates a view that Siegfried Holding may simply track peers rather than stand out. This can cap enthusiasm for aggressive re rating.
The lower target also underlines sensitivity to valuation assumptions, with bearish analysts signaling that smaller changes in inputs can meaningfully affect what they see as a fair price.

What's in the News

Siegfried AG updated earnings guidance for 2026, with the Group now expecting high single digit percent growth in net sales in local currencies, compared with previously low single digit guidance (Key Developments).
The revised 2026 outlook indicates that management has adjusted its view on the pace of net sales growth in local currencies relative to prior guidance (Key Developments).
Investors tracking Siegfried Holding now have a higher reference point for the company’s 2026 net sales guidance in local terms than was communicated earlier (Key Developments).

Valuation Changes

Fair Value: CHF 103.91 is unchanged, so the central valuation anchor for Siegfried Holding remains the same.
Discount Rate: risen slightly from 4.80% to 4.85%, indicating a marginally higher required return in the updated model.
Revenue Growth: kept broadly stable at about 6.93%, with only a very small technical adjustment in the underlying assumption.
Net Profit Margin: held effectively flat at about 14.06%, indicating no material shift in expected profitability assumptions.
Future P/E: increased from 22.53x to 22.56x, reflecting a very small change in the valuation multiple applied to projected earnings.

2 views

Key Takeaways

Pharma outsourcing and demand for supply chain resilience position Siegfried for long-term growth, recurring revenues, and stable margins.
Investments in technology and efficient operations, plus strategic acquisitions, support higher-margin growth and improved profitability.
Intense pricing pressure, execution risks in expansion, and sector consolidation threaten Siegfried's margins, growth, and competitiveness amid limited pricing power and long project timelines.

Catalysts

About Siegfried Holding

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.What are the underlying business or industry changes driving this perspective?

The accelerating trend of pharmaceutical outsourcing, particularly among small and mid-sized pharma companies that lack in-house manufacturing capabilities, positions Siegfried to capture increased volumes and long-term contracts, directly supporting top-line revenue growth and underpinning forward sales visibility.
Industry-wide heightened demand for supply chain resilience and the need for diversified, reliable manufacturing partners after recent disruptions has enabled Siegfried to secure new dual-supply agreements (e.g., for blockbuster drugs), which should increase recurring revenues and provide margin stability through long-duration relationships.
Continuing investments in high-value technology platforms and capacity expansions (e.g., steriles, biologics, GLP-1 capabilities) increase Siegfried's exposure to fast-growing drug categories, supporting higher-margin revenue growth and sustaining overall EBITDA expansion through the mid-term.
Enhanced operational efficiency measures (such as Project FALCON) have already released significant cash flow and reduced inventories, paving the way for improved working capital management and freeing up additional funds for growth investments, thus supporting higher future net income and return on capital.
Active and disciplined M&A strategy, enabled by a strong balance sheet and ample debt capacity, is expected to deliver inorganic revenue and earnings growth, providing incremental synergies and scale benefits that can further expand margins and accelerate EPS growth.

Siegfried Holding Earnings and Revenue Growth

Siegfried Holding Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Siegfried Holding's revenue will grow by 6.9% annually over the next 3 years.
Analysts assume that profit margins will increase from 12.7% today to 14.1% in 3 years time.
Analysts expect earnings to reach CHF 228.2 million (and earnings per share of CHF 5.2) by about June 2029, up from CHF 168.7 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as CHF264.8 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 22.9x on those 2029 earnings, up from 21.2x today. This future PE is lower than the current PE for the GB Life Sciences industry at 38.6x.
Analysts expect the number of shares outstanding to decline by 0.13% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 4.85%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Increasing pressure on drug pricing, especially from potential U.S. drug price cuts, could adversely affect Siegfried's top-line growth and compress margins over the mid
to long term, as customers seek greater cost reductions from suppliers and CDMOs like Siegfried are forced to compete primarily on price, impacting earnings and profitability.
Siegfried's recent growth has skewed more towards volume rather than pricing power, suggesting limited ability to increase prices in a competitive CDMO market, which, if cost inflation continues or intensifies, could exert sustained pressure on net margins and earnings.
The company faces significant ramp-up periods and long revenue recognition cycles for major CapEx projects (e.g., Minden and Hameln), making near-term revenue and cash flow dependent on successful and timely ramp-up of these facilities; any delays or underutilization could negatively impact both revenue growth and return on invested capital over several years.
Siegfried's ambition to expand its technology offering, particularly into new modalities such as cell and gene therapies, exposes the company to execution risk and potential margin dilution, given its current limited experience in commercial manufacturing and integration of new sites, which could impact profitability if market penetration or operational scaling falls short.
The ongoing trend of industry consolidation and greater automation/digitalization in the CDMO sector favors larger-scale players; mid-sized Siegfried could lose market share or bargaining power to better-capitalized or integrated competitors, leading to slower revenue growth and possibly negative effects on long-term earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of CHF103.91 for Siegfried Holding based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF126.0, and the most bearish reporting a price target of just CHF85.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CHF1.6 billion, earnings will come to CHF228.2 million, and it would be trading on a PE ratio of 22.9x, assuming you use a discount rate of 4.8%.
Given the current share price of CHF81.8, the analyst price target of CHF103.91 is 21.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Siegfried Holding?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Pharmaceutical Outsourcing And Supply Chain Resilience Will Drive Future Expansion